RNA Therapeutics Leadership:
Avidity Biosciences NASDAQ:RNA is at the forefront of RNA therapeutics with its innovative antibody-oligonucleotide conjugates (AOCs). Its lead candidate, Del-desiran (AOC 1001), targeting myotonic dystrophy type 1, is on the verge of a pivotal trial. Approval could significantly boost earnings.
Strategic Partnership:
Avidity's...